Why Moderna Is Shooting Higher Today

Coronavirus stock Moderna (NASDAQ: MRNA) was up by nearly 8% in mid-afternoon trading on Thursday. Two pieces of news about the company's coronavirus vaccine seem to be supporting this rise.

The first is Moderna's announcement that dosing of participants has begun in a phase 1/2 clinical trial for mRNA-1273 in Japan. This study, which is being led by Japanese pharmaceutical company Takeda (NYSE: TAK), seeks to enroll 200 people aged 20 and older.

Image source: Getty Images.

Source Fool.com